- Home
- BNT vs BMRN Comparison
BNT vs BMRN Comparison
Compare BNT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNT | BMRN |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | BNT | BMRN |
|---|---|---|
| Price | $45.37 | $52.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $88.42 |
| AVG Volume (30 Days) | 29.2K | ★ 2.9M |
| Earning Date | 11-13-2025 | 10-27-2025 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | 0.15 | ★ 59.53 |
| EPS | ★ 4.29 | 2.68 |
| Revenue | ★ $14,328,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | N/A | $7.57 |
| P/E Ratio | ★ $10.67 | $19.89 |
| Revenue Growth | ★ 35.36 | 12.39 |
| 52 Week Low | $29.13 | $50.76 |
| 52 Week High | $49.44 | $73.51 |
Technical Indicators
Market Signals| Indicator | BNT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 40.55 |
| Support Level | $45.89 | $52.55 |
| Resistance Level | $47.83 | $54.33 |
| Average True Range (ATR) | 0.84 | 1.27 |
| MACD | 0.24 | -0.23 |
| Stochastic Oscillator | 10.50 | 23.42 |
Price Performance
Historical ComparisonAbout BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. It is organized into three reporting segments: Direct Insurance, Reinsurance, and Pension Risk Transfer (PRT).
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.